When

Thursday, March 09, 2017

6:30 PM - 8:30 PM

WheRE

New York, New York

Morton's Steakhouse
NY Boardroom A
551 5th Avenue
New York, NY

faculty

Timothy R. Deer, MD, DABPM (Prerecorded)
President and Chief Executive Officer
Center for Pain Relief, Inc.
Charleston, West Virginia

Charles E. Argoff, MD
Professor of Neurology 
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, New York

Michael Saulino, MD, PhD
Assistant Professor
Department of Rehabilitation Medicine
Sidney Kimmel Medical College
Philadelphia, PA
Physiatrist, MossRehab
Elkins Park, PA

Registration for this meeting is full. You may still register but will be placed on a waiting list.  We will contact you should space permit your attendance. 

 

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Jazz Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of interventional pain specialists as well as fellows from interventional pain programs.

Statement of Need/Program Overview

Many patients with severe chronic pain are unable to derive adequate pain relief or achieve their functional goals using conventional treatment strategies.1,2 For some of these individuals, delivering medications directly to the intrathecal space in the spine can be a safe and effective therapeutic approach.3,4 The US Food and Drug Administration (FDA) has approved 2 analgesics—ziconotide and morphine—for intrathecal delivery in patients with severe chronic pain.5,6 Yet this treatment modality is largely underutilized, in part because patient selection has been poor historically, systemic barriers can be formidable, and safety concerns—particularly, opioid-induced respiratory depression—often take center stage in the published literature.7,8 During this Meet-the-Professors™ CME workshop, expert faculty will discuss newly published Polyanalgesic Consensus Conference recommendations on intrathecal therapy for chronic pain. Key educational themes include identifying patients with severe chronic pain who are good candidates for intrathecal drug delivery, initiating treatment with FDA-approved intrathecal analgesics, longitudinally monitoring patients with implanted pumps, and tailoring intrathecal therapy based on analgesia, functional outcomes, and treatment-emergent adverse effects.

References

  1. National Research Council. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Institute of Medicine. Washington, DC: The National Academies Press; 2011.
  2. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581-624.
  3. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56(8):516-520.
  4. Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17(4):354-372.
  5. Ver Donck A, Vranken JH, Puylaert M, et al. Intrathecal drug administration in chronic pain syndromes. Pain Pract. 2014;14(5):461-476.
  6. Kim P, Grigsby E, Deer T, et al. Effectiveness and safety of intrathecal ziconotide as the first agent in pump for adult patients with severe chronic pain. Presented at the 22nd Annual Napa Pain Conference; August 27-29, 2015; Napa, CA.
  7. Deer TR, Pope JE, Hayek S, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017 Jan 2. [Epub ahead of print].
  8. Coffey RJ, Owens ML, Broste SK, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111(4):881-891.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with severe chronic pain as candidates for intrathecal therapy based on comprehensive preimplantation work-ups
  • Discuss the clinical profiles and prescribing considerations for analgesics that have been FDA-approved for intrathecal delivery
  • Describe best-practice strategies for trialing, pump implantation, and postoperative monitoring when patients with severe chronic pain are selected for intrathecal therapy
  • Individualize intrathecal therapy for severe chronic pain based on the most current evidence for drug selection, updated guideline recommendations, and other patient-specific factors
  • Monitor patients being treated intrathecal therapy over time to guide therapeutic adjustments that reflect analgesia, functional outcomes, and treatment-emergent adverse events

Faculty

Timothy R. Deer, MD, DABPM (Prerecorded)
President and Chief Executive Officer
Center for Pain Relief, Inc.
Charleston, West Virginia

Charles E. Argoff, MD
Professor of Neurology 
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, New York

Michael Saulino, MD, PhD
Assistant Professor
Department of Rehabilitation Medicine
Sidney Kimmel Medical College
Philadelphia, PA
Physiatrist, MossRehab
Elkins Park, PA

Program Agenda

6:30 PM – 6:35 PM: Faculty Introductions

6:35 PM – 6:45 PM: Fundamentals of Intrathecal Drug Delivery for Severe Chronic Pain

6:45 PM – 7:00 PM: Selecting Patients and Initiating Intrathecal Medications

7:00 PM – 7:15 PM: Prerecorded Demonstrations of Pump Implantation Surgery

7:15 PM – 7:30 PM: Ongoing Patient Monitoring of Maintenance With Intrathecal Therapy

7:30 PM –8:15 PM: Case-Study Workshop

8:15 PM –8:30 PM: Ask the Experts Question and Answer Session

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Mike Remsen prior to the live event at mremsen@integritasgrp.com.

For information about the accreditation of this program, please contact Global at 646-350-0906 or cme@globaleducationgroup.com.

Register Now

attend event